Anavex Life Sciences Corp.
AVXL
$2.75
-$0.10-3.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 72.97% | 27.69% | 14.08% | -7.85% | -15.99% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -220.63% | 18.27% | 15.14% | 22.37% | -6.19% |
| Change in Net Operating Assets | -469.20% | -186.20% | -383.17% | -253.20% | 20.58% |
| Cash from Operations | 21.04% | -9.54% | 4.32% | -26.72% | -23.65% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,552.60% | 658.46% | 278.30% | 1.39% | -87.32% |
| Repurchase of Common Stock | 80.33% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 9,503.44% | 614.79% | 256.85% | -21.22% | -103.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 145.65% | 149.34% | 147.73% | -57.19% | -134.06% |